Elevated cardiac troponin T is associated with increased left ventricular mass index and predicts mortality in

Dursun Duman1, Sena Tokay, Ahmet Toprak

  • 1Haydarpasa Numune Training and Research Hospital, Department of Cardiology, Ahmet Refik Sok. Ceylan Apt. 19/5, Ciftehavuzlar, 81060 Istanbul, Turkey. drduman@excite.com

Insights

Elevated cardiac troponin T (cTnT) predicts mortality in continuous ambulatory peritoneal dialysis (CAPD) patients. Higher cTnT levels are linked to increased left ventricular mass, a key factor in cardiovascular disease risk.

Area of Science:

  • Nephrology
  • Cardiology
  • Biomarkers

Background:

  • End-stage renal disease (ESRD) patients face high mortality, primarily from cardiovascular (CV) events.
  • Elevated cardiac troponin T (cTnT) correlates with left ventricular mass index (LVMI) and predicts poor outcomes in hemodialysis patients.

Purpose of the Study:

  • To investigate the prognostic value of cTnT in continuous ambulatory peritoneal dialysis (CAPD) patients.
  • To examine the relationship between cTnT levels and left ventricular mass in CAPD patients.

Main Methods:

  • Prospective study of 65 CAPD patients (mean age 56 years, 36% males) with no acute coronary syndrome in the prior 28 days.
  • 48-month follow-up to evaluate total and CV mortality.
  • Univariate and multivariate logistic regression analyses, including assessment of cTnT, LVMI, diabetes, albumin, and age.

Main Results:

  • Elevated cTnT (> /=0.035 ng/ml) and age independently predicted total mortality.
  • cTnT > /=0.035 ng/ml was the sole independent predictor of CV mortality.
  • A significant positive correlation was found between serum cTnT and LVMI (rho = 0.41, P<0.002).
  • cTnI, CK, and CK-MB levels did not correlate with mortality.

Conclusions:

  • Elevated serum cTnT is a significant predictor of total and CV mortality in CAPD patients.
  • cTnT levels are associated with increased LVMI in this population.
  • cTnI is not a reliable mortality predictor in CAPD patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...